|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1992-10-15
|
|
pubmed:abstractText |
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-1250
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
161
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
254-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1355693-Administration, Oral,
pubmed-meshheading:1355693-Antipsychotic Agents,
pubmed-meshheading:1355693-Bipolar Disorder,
pubmed-meshheading:1355693-Creatine Kinase,
pubmed-meshheading:1355693-Female,
pubmed-meshheading:1355693-Follow-Up Studies,
pubmed-meshheading:1355693-Haloperidol,
pubmed-meshheading:1355693-Hospitalization,
pubmed-meshheading:1355693-Humans,
pubmed-meshheading:1355693-Injections, Intramuscular,
pubmed-meshheading:1355693-Male,
pubmed-meshheading:1355693-Methotrimeprazine,
pubmed-meshheading:1355693-Neuroleptic Malignant Syndrome,
pubmed-meshheading:1355693-Neurologic Examination,
pubmed-meshheading:1355693-Perphenazine,
pubmed-meshheading:1355693-Prospective Studies,
pubmed-meshheading:1355693-Risk Factors,
pubmed-meshheading:1355693-Schizophrenia,
pubmed-meshheading:1355693-Schizophrenic Psychology
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
|
|
pubmed:affiliation |
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
